Verrica Pharmaceuticals Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Verrica Pharmaceuticals Inc. (VRCA) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00.
- Verrica Pharmaceuticals Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $0.00.
- Verrica Pharmaceuticals Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- Verrica Pharmaceuticals Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-11 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-11 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-02 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-17 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |